دواء إيميدي معدل للمناعة (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "دواء إيميدي معدل للمناعة" in Arabic language version.

refsWebsite
Global rank Arabic rank
2nd place
5th place
4th place
6th place
11th place
86th place
6th place
3rd place
low place
low place
14th place
41st place
18th place
33rd place

archive.org

archive.today

doi.org

  • Knight، R (أغسطس 2005). "IMiDs: a novel class of immunomodulators". Seminars in Oncology. ج. 32 ع. 4 Suppl 5: S24–S30. DOI:10.1053/j.seminoncol.2005.06.018. PMID:16085014.
  • Aragon-Ching AB، Li H، Gardner ER، Figg WD (2007). "Thalidomide analogues as anticancer drugs". Recent Pat Anti-Cancer Drug Discov. ج. 2 ع. 2: 167–174. DOI:10.2174/157489207780832478. PMC:2048745. PMID:17975653.
  • Prommer، E. E. (20 أكتوبر 2009). "Review Article: Palliative Oncology: Thalidomide". American Journal of Hospice and Palliative Medicine. ج. 27 ع. 3: 198–204. DOI:10.1177/1049909109348981. PMID:19843880. S2CID:24167431.
  • Mazzoccoli، L؛ Cadoso, SH؛ Amarante, GW؛ de Souza, MV؛ Domingues, R؛ Machado, MA؛ de Almeida, MV؛ Teixeira, HC (يوليو 2012). "Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10". Biomedicine & Pharmacotherapy. ج. 66 ع. 5: 323–9. DOI:10.1016/j.biopha.2012.05.001. PMID:22770990.
  • Bartlett، J. Blake؛ Dredge, Keith؛ Dalgleish, Angus G. (1 أبريل 2004). "Timeline: The evolution of thalidomide and its IMiD derivatives as anticancer agents". Nature Reviews Cancer. ج. 4 ع. 4: 314–322. DOI:10.1038/nrc1323. PMID:15057291. S2CID:7293027.
  • D'Amato RJ، Lentzsch S، Anderson KC، Rogers MS (ديسمبر 2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma". Semin. Oncol. ج. 28 ع. 6: 597–601. DOI:10.1016/S0093-7754(01)90031-4. PMID:11740816.
  • Zeldis، Jerome B.؛ Knight, Robert؛ Hussein, Mohamad؛ Chopra, Rajesh؛ Muller, George (1 مارس 2011). "A review of the history, properties, and use of the immunomodulatory compound lenalidomide". Annals of the New York Academy of Sciences. ج. 1222 ع. 1: 76–82. Bibcode:2011NYASA1222...76Z. DOI:10.1111/j.1749-6632.2011.05974.x. PMID:21434945. S2CID:5336195.
  • Zimmerman، Todd (1 مايو 2009). "Immunomodulatory agents in oncology". Update on Cancer Therapeutics. ج. 3 ع. 4: 170–181. DOI:10.1016/j.uct.2009.03.003.
  • D'Amato، RJ؛ Lentzsch, S؛ Anderson, KC؛ Rogers, MS (ديسمبر 2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma". Seminars in Oncology. ج. 28 ع. 6: 597–601. DOI:10.1016/S0093-7754(01)90031-4. PMID:11740816.
  • Man، Hon-Wah؛ Corral, Laura G؛ Stirling, David I؛ Muller, George W (1 أكتوبر 2003). "α-Fluoro-substituted thalidomide analogues". Bioorganic & Medicinal Chemistry Letters. ج. 13 ع. 20: 3415–3417. DOI:10.1016/S0960-894X(03)00778-9. PMID:14505639.
  • Man، Hon-Wah؛ Schafer, Peter؛ Wong, Lu Min؛ Patterson, Rebecca T.؛ Corral, Laura G.؛ Raymon, Heather؛ Blease, Kate؛ Leisten, Jim؛ Shirley, Michael A.؛ Tang, Yang؛ Babusis, Darius M.؛ Chen, Roger؛ Stirling, Dave؛ Muller, George W. (26 مارس 2009). "Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor". Journal of Medicinal Chemistry. ج. 52 ع. 6: 1522–4. DOI:10.1021/jm900210d. PMID:19256507.
  • Muller، George W.؛ Corral, Laura G.؛ Shire, Mary G.؛ Wang, Hua؛ Moreira, Andre؛ Kaplan, Gilla؛ Stirling, David I. (1 يناير 1996). "Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity". Journal of Medicinal Chemistry. ج. 39 ع. 17: 3238–3240. DOI:10.1021/jm9603328. PMID:8765505.
  • Vallet، S؛ Witzens-Harig, M؛ Jaeger, D؛ Podar, K (مارس 2012). "Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies". Expert Opinion on Pharmacotherapy. ج. 13 ع. 4: 473–494. DOI:10.1517/14656566.2012.656091. PMID:22324734. S2CID:7981368.
  • Sedlarikova, L؛ Kubiczkova, L؛ Sevcikova, S؛ Hajek, R (أكتوبر 2012). "Mechanism of immunomodulatory drugs in multiple myeloma". Leukemia Research. ج. 36 ع. 10: 1218–1224. DOI:10.1016/j.leukres.2012.05.010. PMID:22727252.

harvard.edu

ui.adsabs.harvard.edu

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Knight، R (أغسطس 2005). "IMiDs: a novel class of immunomodulators". Seminars in Oncology. ج. 32 ع. 4 Suppl 5: S24–S30. DOI:10.1053/j.seminoncol.2005.06.018. PMID:16085014.
  • Aragon-Ching AB، Li H، Gardner ER، Figg WD (2007). "Thalidomide analogues as anticancer drugs". Recent Pat Anti-Cancer Drug Discov. ج. 2 ع. 2: 167–174. DOI:10.2174/157489207780832478. PMC:2048745. PMID:17975653.
  • Prommer، E. E. (20 أكتوبر 2009). "Review Article: Palliative Oncology: Thalidomide". American Journal of Hospice and Palliative Medicine. ج. 27 ع. 3: 198–204. DOI:10.1177/1049909109348981. PMID:19843880. S2CID:24167431.
  • Mazzoccoli، L؛ Cadoso, SH؛ Amarante, GW؛ de Souza, MV؛ Domingues, R؛ Machado, MA؛ de Almeida, MV؛ Teixeira, HC (يوليو 2012). "Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10". Biomedicine & Pharmacotherapy. ج. 66 ع. 5: 323–9. DOI:10.1016/j.biopha.2012.05.001. PMID:22770990.
  • Bartlett، J. Blake؛ Dredge, Keith؛ Dalgleish, Angus G. (1 أبريل 2004). "Timeline: The evolution of thalidomide and its IMiD derivatives as anticancer agents". Nature Reviews Cancer. ج. 4 ع. 4: 314–322. DOI:10.1038/nrc1323. PMID:15057291. S2CID:7293027.
  • D'Amato RJ، Lentzsch S، Anderson KC، Rogers MS (ديسمبر 2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma". Semin. Oncol. ج. 28 ع. 6: 597–601. DOI:10.1016/S0093-7754(01)90031-4. PMID:11740816.
  • Zeldis، Jerome B.؛ Knight, Robert؛ Hussein, Mohamad؛ Chopra, Rajesh؛ Muller, George (1 مارس 2011). "A review of the history, properties, and use of the immunomodulatory compound lenalidomide". Annals of the New York Academy of Sciences. ج. 1222 ع. 1: 76–82. Bibcode:2011NYASA1222...76Z. DOI:10.1111/j.1749-6632.2011.05974.x. PMID:21434945. S2CID:5336195.
  • D'Amato، RJ؛ Lentzsch, S؛ Anderson, KC؛ Rogers, MS (ديسمبر 2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma". Seminars in Oncology. ج. 28 ع. 6: 597–601. DOI:10.1016/S0093-7754(01)90031-4. PMID:11740816.
  • Man، Hon-Wah؛ Corral, Laura G؛ Stirling, David I؛ Muller, George W (1 أكتوبر 2003). "α-Fluoro-substituted thalidomide analogues". Bioorganic & Medicinal Chemistry Letters. ج. 13 ع. 20: 3415–3417. DOI:10.1016/S0960-894X(03)00778-9. PMID:14505639.
  • Man، Hon-Wah؛ Schafer, Peter؛ Wong, Lu Min؛ Patterson, Rebecca T.؛ Corral, Laura G.؛ Raymon, Heather؛ Blease, Kate؛ Leisten, Jim؛ Shirley, Michael A.؛ Tang, Yang؛ Babusis, Darius M.؛ Chen, Roger؛ Stirling, Dave؛ Muller, George W. (26 مارس 2009). "Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor". Journal of Medicinal Chemistry. ج. 52 ع. 6: 1522–4. DOI:10.1021/jm900210d. PMID:19256507.
  • Muller، George W.؛ Corral, Laura G.؛ Shire, Mary G.؛ Wang, Hua؛ Moreira, Andre؛ Kaplan, Gilla؛ Stirling, David I. (1 يناير 1996). "Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity". Journal of Medicinal Chemistry. ج. 39 ع. 17: 3238–3240. DOI:10.1021/jm9603328. PMID:8765505.
  • Vallet، S؛ Witzens-Harig, M؛ Jaeger, D؛ Podar, K (مارس 2012). "Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies". Expert Opinion on Pharmacotherapy. ج. 13 ع. 4: 473–494. DOI:10.1517/14656566.2012.656091. PMID:22324734. S2CID:7981368.
  • Sedlarikova, L؛ Kubiczkova, L؛ Sevcikova, S؛ Hajek, R (أكتوبر 2012). "Mechanism of immunomodulatory drugs in multiple myeloma". Leukemia Research. ج. 36 ع. 10: 1218–1224. DOI:10.1016/j.leukres.2012.05.010. PMID:22727252.

ncbi.nlm.nih.gov

oncozine.com

semanticscholar.org

api.semanticscholar.org